Work

The effectiveness of ixekizumab and other bDMARDs at 12-months for patients with PsA in real-world settings: Results from the PRO-SPIRIT study

Year: 2024

Type: conference-paper

Abstract: Introduction: GRAPPA and EULAR recommendations highlight the importance of individualised psoriatic arthritis (PsA) treatment and suggest treatment target should be clinical remission (REM) or low/minimal disease activity (LDA/MDA) across key PsA domains [ref:1], [ref:2]. [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/24dgrh177

Authors: Alten, Rieke H. E., Krüger, Klaus, Werner, Stephanie, Russ, Hagen, Ng, Khai Jing, Ngantcha, Marcus, Kill, Angela, Schwaneck, Eva Christina, Kristensen, Lars Erik, Mcgonagle, Dennis

Institutions: Schlosspark-Klinik, Eli Lilly (United States), Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer, University of Copenhagen, University of Leeds

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6927308515

FWCI:

Cites:

Cited by:

Related to: